Department of Nuclear Medicine, Santa Maria Goretti Hospital, Latina, Italy.
Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
Expert Rev Med Devices. 2022 Jul;19(7):591-598. doi: 10.1080/17434440.2022.2117612. Epub 2022 Aug 28.
We assessed the role of digital PET/CT (dPET/CT) with F-FACBC in patients affected by castration-resistant prostate cancer with PSA levels ≤ 3 ng/mL (early CRPC), no lesions detectable at cross-sectional imaging (CIM) and bone scan (BS).
Clinical data of patients submitted to F-FACBC dPET/CT were retrospectively reviewed. PET/CT results were analyzed: lesions' number, location, and, in case of positive lymph nodes, largest node's short axis (i.e. SA) were annotated. According to PET/CT's results, patients with F-FACBC-avid lesions were further stratified into 1) unifocal; 2) oligometastatic (≤ 5 lesions); 3) disseminated (> 6 lesions).
Twenty-four patients were enrolled. F-FACBC dPET/CT was positive in 21 out of 24 patients (87.5%). Thirteen patients (54.1%) showed recurrence in pelvic region, seven of whom with pelvic nodes' involvement, while eight cases (33.3%) presented F-FACBC-avid metastases to extra-pelvic nodes or bone. Average SA of PET-positive nodes resulted in 8.9 ± 3 mm. Patients were categorized as unifocal in four cases (26.6%), oligometastatic in 10 subjects (66.6%) and disseminated in 1 case (0.6%). PET/CT impacted on clinical management in 14 cases (58.3%).
F-FACBC dPET/CT detected M1 status in 33.3% of early CRPC patients, significantly impacting on clinical management.
我们评估了 F-FACBC 标记的数字正电子发射断层扫描/计算机断层扫描(dPET/CT)在前列腺特异性抗原(PSA)水平≤3ng/ml(早期去势抵抗性前列腺癌,CRPC)、横断面成像(CIM)和骨扫描(BS)无可检测病灶的患者中的作用。
回顾性分析了接受 F-FACBC dPET/CT 的患者的临床数据。分析了 PET/CT 结果:记录病灶数量、位置,以及在阳性淋巴结的情况下,记录最大淋巴结短轴(即短轴)。根据 PET/CT 结果,将 F-FACBC 阳性的患者进一步分为 1)单灶;2)寡转移(≤5 个病灶);3)广泛转移(>6 个病灶)。
共纳入 24 例患者。24 例患者中,21 例(87.5%)F-FACBC dPET/CT 阳性。13 例(54.1%)患者出现盆腔区域复发,其中 7 例伴有盆腔淋巴结受累,8 例(33.3%)出现骨盆外淋巴结或骨骼的 F-FACBC 阳性转移。阳性淋巴结的平均短轴为 8.9±3mm。4 例(26.6%)患者为单灶,10 例(66.6%)患者为寡转移,1 例(0.6%)患者为广泛转移。14 例(58.3%)患者的 PET/CT 影响了临床管理。
F-FACBC dPET/CT 在 33.3%的早期 CRPC 患者中检测到 M1 状态,显著影响了临床管理。